Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of “Hold” by Brokerages

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) have received an average recommendation of “Hold” from the five research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $12.6667.

A number of research analysts have recently issued reports on VRCA shares. Lake Street Capital assumed coverage on shares of Verrica Pharmaceuticals in a research report on Thursday, August 27th. They issued a “buy” rating and a $9.00 price objective on the stock. HC Wainwright started coverage on Verrica Pharmaceuticals in a research report on Tuesday, May 26th. They set a “buy” rating and a $12.00 price target on the stock. Wall Street Zen lowered Verrica Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, July 15th.

Institutional Trading of Verrica Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC increased its holdings in shares of Verrica Pharmaceuticals by 75.1% in the fourth quarter. Armistice Capital LLC now owns 1,118,925 shares of the company’s stock valued at $9,298,000 after purchasing an additional 479,732 shares during the period. Affinity Asset Advisors LLC acquired a new stake in shares of Verrica Pharmaceuticals during the fourth quarter worth about $5,878,000. Velan Capital Investment Management LP purchased a new stake in Verrica Pharmaceuticals in the fourth quarter valued at approximately $3,919,000. Boothbay Fund Management LLC purchased a new stake in Verrica Pharmaceuticals in the third quarter valued at approximately $1,210,000. Finally, Kalehua Capital Management LLC purchased a new position in Verrica Pharmaceuticals during the 4th quarter worth approximately $1,959,000. Institutional investors and hedge funds own 42.45% of the company’s stock.

Verrica Pharmaceuticals Stock Performance

Shares of Verrica Pharmaceuticals stock opened at $4.91 on Monday. The company has a market capitalization of $84.35 million, a PE ratio of -2.94 and a beta of 1.49. The company has a 50-day simple moving average of $5.35 and a two-hundred day simple moving average of $5.76. Verrica Pharmaceuticals has a one year low of $3.28 and a one year high of $9.82. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.33 and a current ratio of 1.45.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of topical therapies for dermatological conditions. Its lead investigational product, VP-102, is a standardized formulation of cantharidin in a pre-measured applicator designed to treat molluscum contagiosum and common warts. Verrica’s approach emphasizes consistency of dosing and patient convenience, aiming to improve upon off‐label use of existing treatments.

Beyond VP-102, Verrica is advancing VP-103, a next‐generation topical candidate intended to optimize tolerability while maintaining efficacy against viral skin lesions.